Literature DB >> 34417318

Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy: A Post Hoc Analysis from the SONAR Trial.

Simke W Waijer1, Sieta T de Vries1, Robert Busch2, Di Xie3, Ron T Gansevoort4, Fan Fan Hou3, Jose L Górriz5, Gozewijn D Laverman6,7, Luca De Nicola8, Julio Pascual9, Michele Provenzano8, Pablo E Pergola10, Sydney C W Tang11, Christoph Wanner12, Philippe Zaoui13, Hans-Henrik Parving14, Dick de Zeeuw1, Hiddo J L Heerspink15.   

Abstract

Entities:  

Keywords:  chronic kidney disease; eGFR decline; endothelin receptor antagonist; randomized controlled trials; type 2 diabetes

Mesh：

Substances：

Year:  2021        PMID： 34417318      PMCID： PMC8806091          DOI： 10.1681/ASN.2021040498

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  5 in total

1.  Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Authors:  Hiddo J L Heerspink; Hans-Henrik Parving; Dennis L Andress; George Bakris; Ricardo Correa-Rotter; Fan-Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John J V McMurray; Joel Z Melnick; Michael G Miller; Pablo E Pergola; Vlado Perkovic; Sheldon Tobe; Tingting Yi; Melissa Wigderson; Dick de Zeeuw
Journal:  Lancet       Date:  2019-04-14       Impact factor: 79.321

2.  Dapagliflozin in Patients with Chronic Kidney Disease.

Authors:  Hiddo J L Heerspink; Bergur V Stefánsson; Ricardo Correa-Rotter; Glenn M Chertow; Tom Greene; Fan-Fan Hou; Johannes F E Mann; John J V McMurray; Magnus Lindberg; Peter Rossing; C David Sjöström; Roberto D Toto; Anna-Maria Langkilde; David C Wheeler
Journal:  N Engl J Med       Date:  2020-09-24       Impact factor: 91.245

3.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

4.  Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.

Authors:  Hiddo J L Heerspink; Dennis L Andress; George Bakris; John J Brennan; Ricardo Correa-Rotter; Jyotirmoy Dey; Fan Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John McMurray; Vlado Perkovic; Sheldon Tobe; Melissa Wigderson; Hans-Henrik Parving; Dick de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2018-03-09       Impact factor: 6.577

5.  Baseline characteristics and enrichment results from the SONAR trial.

Authors:  Hiddo J L Heerspink; Dennis L Andress; George Bakris; John J Brennan; Ricardo Correa-Rotter; Fan Fan Hou; Dalane W Kitzman; Donald Kohan; Hirofumi Makino; John McMurray; Vlado Perkovic; Sheldon Tobe; Melissa Wigderson; Tingting Yi; Hans-Henrik Parving; Dick de Zeeuw
Journal:  Diabetes Obes Metab       Date:  2018-05-01       Impact factor: 6.577
  5 in total
  2 in total

1.  Endothelin Receptor Antagonists for Kidney Protection: Lessons from the SONAR Trial.

Authors:  Hiddo J L Heerspink; Dick de Zeeuw
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-28       Impact factor: 10.614

2.  Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study.

Authors:  Satoshi Miyamoto; Hiddo J L Heerspink; Dick de Zeeuw; Masao Toyoda; Daisuke Suzuki; Takashi Hatanaka; Tohru Nakamura; Shinji Kamei; Satoshi Murao; Kazuyuki Hida; Shinichiro Ando; Hiroaki Akai; Yasushi Takahashi; Daisuke Koya; Munehiro Kitada; Hisashi Sugano; Tomokazu Nunoue; Akihiko Nakamura; Motofumi Sasaki; Tatsuaki Nakatou; Kei Fujimoto; Daiji Kawanami; Takashi Wada; Nobuyuki Miyatake; Michihiro Yoshida; Kenichi Shikata
Journal:  Diabetes Obes Metab       Date:  2022-05-18       Impact factor: 6.408
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.